Literature DB >> 16762402

Estrogen receptor alpha polymorphism and venous thromboembolism in male and female: data from the EDITH study.

Emmanuel Oger1, Karine Lacut, Bernard Mercier, Grégoire Le Gal, Christophe Leroyer, Elisabeth Pasquier, Claude Férec, Dominique Mottier.   

Abstract

BACKGROUND: Association between estrogen receptor (ER) alpha polymorphism c.454-397 T>C and venous thromboembolism (VTE) has been reported in postmenopausal women. Comprehensive data are lacking. We herein evaluated the risk for VTE related to c.454-397 T>C ER alpha gene polymorphism in both men and women. PATIENTS/
METHODS: The EDITH Study enrolled consecutive patients, aged over 18 years, hospitalized between May 2000 and December 2004 in Brest University Hospital with an objectively proven symptomatic VTE. For each case, one control who matched the case for age within a five-year age band, gender and major acquired risk factors, was selected. The present analysis was restricted to 677 cases with a VTE event not related to major acquired risk factors and their matched controls. RESULTS AND
CONCLUSIONS: The relationship between VTE and c.454-397 T>C ER alpha polymorphism was consistent with a dominant model in women and a recessive model in men. Adjusted conditional odds ratios (95% CI) were 1.37 (1.05-1.78) and 1.29 (0.85-1.94) for CT/CC genotypes in women and CC genotype in men respectively compared to TT genotype. Among women hormone use did not substantially modify effect-measure estimate. Our results further extend results from previous studies. Other investigations are required to precise underlying mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762402     DOI: 10.1016/j.thromres.2006.05.002

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Estrogen receptor polymorphisms and the vascular effects of hormone therapy.

Authors:  Jacques Rossouw; Paul Bray; Jingmin Liu; Charles Kooperberg; Judith Hsia; Cora Lewis; Mary Cushman; Denise Bonds; Susan Hendrix; George Papanicolaou; Timothy Howard; David Herrington
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-24       Impact factor: 8.311

2.  ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.

Authors:  Brian Leyland-Jones; Kathryn P Gray; Mark Abramovitz; Mark Bouzyk; Brandon Young; Bradley Long; Roswitha Kammler; Patrizia Dell'Orto; Maria Olivia Biasi; Beat Thürlimann; Vernon Harvey; Patrick Neven; Laurent Arnould; Rudolf Maibach; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Olivia Pagani; Giuseppe Viale; James M Rae; Meredith M Regan
Journal:  Breast Cancer Res Treat       Date:  2015-11-21       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.